新京报讯（记者王卡拉）作为连续八年参展的"全勤生"，阿斯利康在第八届中国国际进口博览会上延续 1000平方米的展台规模，全面展示了其在"推动科学与创新""促进诊疗变革与共同健康""支持可持续发 展"三大举措下的丰硕成果与坚定承诺。本届进博会，阿斯利康举办了30余场活动并宣布多项重磅投资 与合作，带来两款肿瘤创新药的中国首展，再次印证了其依托进博平台，深耕中国、与中国医疗健康产 业同频共振的长期决心。 今年进博会，阿斯利康首次展出了两款最新在华获批用于治疗乳腺癌的肿瘤创新药：荃科得（卡匹色替 片）和达卓优（注射用德达博妥单抗），预计未来五年将惠及16万余名中国乳腺癌患者。阿斯利康旗下 健康科技公司Evinova还与和铂医药达成战略合作，通过深度融合Evinova全球领先的临床试验AI平台与 和铂医药前沿的AI药物研发能力，加速下一代创新药物研发。 阿斯利康在肿瘤领域的探索不仅限于药物创新，更着眼于构建覆盖"筛、诊、治、管"全链路的全病程管 理模式。借助进博会平台，阿斯利康联合临床专家等共同发起前列腺癌早筛公益科普行动，呼吁社会提 升"早筛、早诊、早治"的健康意识，助力前列腺癌防治关口前移。在精准诊断方面，阿斯利 ...

Core Viewpoint - The approval of Datroway, a TROP2-targeted antibody-drug conjugate (ADC) developed by Daiichi Sankyo and AstraZeneca, marks a significant advancement in the treatment of HR-positive, HER2-negative breast cancer in China, addressing a critical need in the oncology market [1][1][1] Group 1: Product Approval - Datroway has received approval from the National Medical Products Administration (NMPA) in China for treating adult patients with unresectable or metastatic HR-positive, HER2-negative breast cancer who have previously undergone endocrine therapy and at least one line of chemotherapy [1][1][1] - This drug is the second ADC utilizing Daiichi Sankyo's proprietary DXd technology to be approved in China, highlighting the company's innovative capabilities in drug development [1][1][1] Group 2: Market Context - Breast cancer is the second most common malignant tumor among women in China, with approximately 357,000 new cases and 75,000 deaths reported in 2022, indicating a significant public health concern [1][1][1] - About 70% of diagnosed breast cancer cases are classified as HR-positive and HER2-negative, which underscores the importance of targeted therapies like Datroway in addressing this patient population [1][1][1]